Co-Authors
This is a "connection" page, showing publications co-authored by CHAAN S NG and AUNG NAING.
Connection Strength
0.904
-
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer. 2021 04; 9(4).
Score: 0.193
-
Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver Tumors. J Comput Assist Tomogr. 2018 May/Jun; 42(3):357-364.
Score: 0.158
-
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemother Pharmacol. 2016 05; 77(5):973-7.
Score: 0.136
-
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Apr; 75(4):869-74.
Score: 0.126
-
Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res. 2011 Sep 15; 17(18):6052-60.
Score: 0.098
-
Targeting hypoxia-inducible factor-1a (HIF-1a) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget. 2014 Nov 15; 5(21):10280-92.
Score: 0.031
-
Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol. 2012 Jul 20; 30(21):2684-90.
Score: 0.026
-
Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity. Mol Cancer Ther. 2011 Jul; 10(7):1300-7.
Score: 0.024
-
Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. Cancer. 2011 Jan 01; 117(1):77-85.
Score: 0.023
-
Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1087-93.
Score: 0.022
-
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res. 2009 Nov 15; 15(22):7061-8.
Score: 0.022
-
Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab. 2009 Nov; 94(11):4423-32.
Score: 0.022
-
A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest New Drugs. 2010 Oct; 28(5):634-40.
Score: 0.021